Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib, durvalumab, and UV1 maintenance in BRCA wild-type recurrent ovarian cancer
NL-OMON53750Phase 2Recruiting
- Sponsor
- Nordic Society of Gynaecological Oncology
- Start
- Mar 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, durvalumab, UV1 and sargramostim in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Nordic Society of Gynaecological Oncology. Primary endpoint: Progression-free survival. Started Mar 2024; status: recruiting.
02
Drugs
olaparibdurvalumabUV1sargramostim
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON53750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53750.